PODD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Insulet Corp (PODD) is not a strong buy at the moment for a beginner investor with a long-term focus. The technical indicators are bearish, and there is no significant positive momentum in trading trends or options sentiment. While the company has shown strong financial growth in the latest quarter, the stock's near-term outlook appears weak, and analysts have recently lowered price targets, indicating limited upside potential in the short term. Given the user's impatience and unwillingness to wait for optimal entry points, it is better to hold off on investing in PODD at this time.
The technical indicators for PODD are bearish. The MACD is below 0 and negatively expanding, RSI is neutral at 27.394, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 241.888), with resistance levels at R1: 259.467 and R2: 264.898. The overall trend suggests weakness in the stock's price movement.
The company has demonstrated strong financial growth in Q3 2025, with revenue up 29.86% YoY, net income up 13.03% YoY, and EPS up 14.81% YoY. Gross margin also increased to 72.22%, reflecting improved profitability. Analysts still maintain a generally positive long-term outlook on the MedTech sector and Insulet's market leadership in diabetes care.
Analysts have recently lowered price targets, citing limited upside potential and narrowing advantages compared to peers. The technical indicators are bearish, and there is no significant positive sentiment in trading trends or options data. Additionally, there is no recent news or event-driven catalysts to support a strong buy recommendation.
In Q3 2025, Insulet Corp reported revenue of $706.3M, up 29.86% YoY. Net income increased to $87.6M, up 13.03% YoY, and EPS grew to $1.24, up 14.81% YoY. Gross margin improved to 72.22%, up 4.17% YoY, indicating strong financial performance.
Analysts have mixed views on PODD. Recent ratings include downgrades and lowered price targets, with Stifel lowering its target to $350 (from $370) and TD Cowen downgrading the stock to Hold with a $294 target. However, some analysts, like Canaccord and Evercore ISI, maintain a bullish long-term outlook, citing the company's leadership in the insulin pump market and growth potential in the diabetes care sector.
